Condition: Advanced Solid Tumor · Sponsor: Jacobio Pharmaceuticals Co., Ltd.
This is a multicenter, open-label, phase I/IIa to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of pan-KRAS inhibitor JAB-23E73 in patients with advanced solid tumors harboring KRAS mutations or amplification. The study consists of 2 phases: Phase 1 Dose Escalation and Phase IIa Dose Expansion.
This description comes directly from the study's public registry record.
Jacobio Pharmaceuticals · 86 10 56315466 · clinicaltrials@jacobiopharma.com
Always discuss trial participation with your own doctor first.
| Anhui Provincial Cancer Hospital | Hefei, Anhui, China | Not Yet Recruiting |
| National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College | Beijing, Beijing Municipality, China | Recruiting |
| Beijing Cancer Hospital | Beijing, Beijing Municipality, China | Recruiting |
| Beijing Chest Hospital | Beijing, Beijing Municipality, China | Recruiting |
| Peking Union Medical College Hospital | Beijing, Beijing Municipality, China | Recruiting |
| Beijing Friendship Hospital, Capital Medical University | Beijing, Beijing Municipality, China | Not Yet Recruiting |
| Fujian cancer Hospital | Fuzhou, Fujian, China | Not Yet Recruiting |
| Sun Yat-sen Memorial Hospital, Sun Yat-sen University | Guangzhou, Guangdong, China | Recruiting |
| Guangxi Medical University Cancer Hospital | Nanning, Guangxi, China | Recruiting |
| National Cancer Center/Cancer Hospital- Langfang Campus, Chinese Academy of Medical Sciences and Peking Union Medical College | Langfang, Hebei, China | Recruiting |
| Harbin Medical University Cancer Hospital | Haerbin, Heilongjiang, China | Recruiting |
| Henan Cancer Hospital | Zhengzhou, Henan, China | Recruiting |
+ 20 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06959615